A Phase 1/2 interventional study of Placebo and HB0056 in Asthma, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.
Among the 251 studies in Asthma with a site in China, this one is the 105th largest by planned enrollment of the 182 interventional ones that give a count, is one of 32 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 55 of the 95 other live ones, and was the 215th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 2 more countries
Ages 18–85
AstraZeneca · Sites in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–70
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 46 · Phase 3 50 · Phase 4 18
First in 1998; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 203 across the 182 interventional studies, 407 across the 69 observational. Of the 116 that completed or were terminated, 30 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
140 of 251 have an industry lead sponsor. The 10 most frequent:
Shanghai Huaota Biopharmaceutical Co., Ltd. is the lead sponsor of 19 studies on the registry; 14 are open to participants now.
Shanghai Huaota Biopharmaceutical Co., Ltd. has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
28 of the studies in Asthma with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06323213Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Efficacy and Safety Study of 610 in Patients With Severe Asthma | 2027-02 |
| NCT06895460Phase 3The First Affiliated Hospital with Nanjing Medical UniversityA Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) | 2027-06-30 |
| NCT06653322Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma | 2027-09 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
Add all 28 to your calendar (.ics) → With an account.
Among the 251 studies in Asthma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if drug HB0056 works to treat severe asthma in adults. It will also learn about the safety of drugHB0056. The main questions it aims to answer are:
Does drug HB0056 lower the number of times participants need to use a rescue inhaler? What medical problems do participants have when taking drug HB0056? Researchers will compare drug HB0056 to a placebo to see if drug HB0056 works to treat severe asthma.
Participants will:
Take drug HB0056 or a placebo Q2W. Keep a diary of their symptoms and the number of times they use a rescue inhaler
Eligible subjects enrolled in this study must meet the following criteria: male or female subjects aged 18-75 years with moderate to severe asthma; weighing ≥ 40 kg with a body mass index between 18-40 kg/m2; having been diagnosed with chronic asthma for at least 1 year prior to screening; receiving moderate- to high-dose inhaled corticosteroids (ICS) for at least 3 months prior to screening; used at least one other asthma control drug, such as LABA, LTRA, etc., which have been stable for at least 1 month prior to screening.
This study consists of 2 parts. Part I is a phase Ib, randomized, double-blind, placebo-controlled, parallel-group, multiple dose-escalation study which is designed to determine the safety, PK, immunogenicity, and preliminary clinical efficacy of multiple doses of HB0056 Injection in subjects with moderate or severe asthma. Part II is a phase II clinical study aimed at exploring the efficacy and safety of different dosing regimens of HB0056 for the treatment of moderate to severe asthma, and recommending the optimal treatment regimen for the phase III clinical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HB0056 SC injection every 2/4 weeks .
Drug: HB0056
Placebo
Drug: Placebo
Placebo
Targeting TSLP and IL-11 IgG1-type Bispecific Antibody
Part I(Phase Ib): AEs
Incidence of participants with adverse events
Time frame: From baseline to week 16
Part I (Phase Ib): Tss_max
The time required to reach the maximum concentration of HB0056 in the bloodstream after administration at steady state.
Time frame: From baseline to week 16
Part II (Phase II): Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Time frame: From baseline to week 12
Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at each evaluation time
Time frame: Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks
Change from baseline in Fractional exhaled nitric oxide(FeNO) at each evaluation time
Time frame: Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks
Change from baseline in forced vital capacity(FVC) at each evaluation time
Time frame: Part II (Phase II): 52 weeks
Change from baseline in The Forced Expiratory Flow 25-75% (FEF 25-75%) at each evaluation time
Time frame: Part II (Phase II): 52 weeks
Change from baseline in peak expiratory flow (PEF) at each evaluation time
Time frame: Part I(Phase Ib): 16 weeks
Change from baseline in Asthma Control Questionnaire( ACQ-6) at each evaluation time
Time frame: Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks
Annualized rate of the severe asthma exacerbation event
Time frame: Part II (Phase II): 52 weeks
Time to the first onset of the severe asthma exacerbation event
Time frame: Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks
Change from baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ(S)) score at each evaluation time point
Time frame: Part II (Phase II): 52 weeks
Incidence of Adverse events (AEs)
Time frame: Part II (Phase II): 56 weeks
Incidence of anti-drug antibodies (ADAs)
Time frame: Part I(Phase Ib): 16 weeksPart II (Phase II): 56 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HB0056
Shanghai Huaota Biopharmaceutical Co., Ltd.